# US 2003/0211613 A1 · Methods of altering calcium transport

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0211613 A1
- Document ID: US20030211613A1
- Status: Published application
- Kind: A1
- Application number: 10/420,637
- Filed: 2003-04-22
- Published: 2003-11-13
- Earliest claimed: 1999-07-09
- Assignees: Matthias A. Hediger
- Inventors: Matthias A. Hediger; Edward M. Brown; Ji-Bin Peng
- Web page: https://patentgrep.com/patent/US20030211613A1

## CPC

- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- A61P 3/14: for calcium homeostasis (vitamin D A61P3/02; parathyroid hormones A61P5/18; calcitonin A61P5/22; osteoporosis A61P19/10; bone metastasis A61P35/04)
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods of altering transmembrane calcium transport by altering expression of a calcium-transport protein are described.

## Claims

### Claim 19

A method modulating transmembrane calcium transport, the method comprising the steps of:
a. providing a cell that expresses a nucleic acid encoding a protein that transports calcium across a membrane, the nucleic acid comprising a nucleotide sequence corresponding to SEQ ID NO:1, or substitutions or modifications of the sequence, wherein the substituted or modified protein transports calcium across a cellular membrane and is at least 75% identical to SEQ ID NO:2 but distinct from EcaC; and
b. contacting the cell with a chemical that interacts with the protein so as to affect its activity, thereby altering a rate of calcium transport across the membrane.

### Claim 20 (depends on 19)

The method of claim 19, wherein the chemical is an antibody.

### Claim 21 (depends on 19)

The method of claim 19, wherein the chemical is a nucleic acid.

### Claim 22 (depends on 19)

The method of claim 19, wherein the chemical is an inhibitor.

### Claim 23 (depends on 19)

The method of claim 19, wherein the cell is an epithelial cell.

### Claim 24 (depends on 19)

The method of claim 19, wherein the cell is a Xenopus laevis oocyte, placenta cell, pancreas cell, prostate cell, kidney cell, gastrointestinal tract cell, liver cell, hair follicle cell, testis cell, or cancer cell.

### Claim 25 (depends on 24)

The method of claim 24, wherein the cell is an esophageal cell, stomach cell, duodenum cell, jejunum cell, or colon cell.

### Claim 26 (depends on 24)

The method of claim 24, wherein the cell is the chronic myelogenous leukemia cell line K562, the colorectal adenocarcinoma cell line SW480, a bone cell, a leukemia cell, a prostate cancer cell, a breast cancer cell, a esophagus cancer cell, a stomach cancer cell, or a colon cancer cell.

### Claim 27 (depends on 19)

The method of claim 19, wherein the chemical alters the transport properties of the protein.

### Claim 28 (depends on 19)

The method of claim 19, wherein the chemical binds to the protein.

### Claim 29 (depends on 19)

The method of claim 19, wherein the protein is integral with the cellular membrane.

### Claim 30 (depends on 19)

The method of claim 19, wherein the protein is present as a free species.

### Claim 31

A method of identifying a chemical capable of altering transmembrane calcium transport, the method comprising the steps of:
a. providing a cell that expresses a nucleic acid encoding a protein that transports calcium across a membrane, the nucleic acid comprising a nucleotide sequence corresponding to SEQ ID NO:1, or substitutions or modifications of the sequence, wherein the substituted or modified protein transports calcium across a cellular membrane and is at least 75% identical to SEQ ID NO:2 but distinct from EcaC, and wherein transformation of the cell causes functional expression of the protein in a membrane of the cell;
b. contacting the membrane with at least one candidate chemical;
c. measuring the transmembrane calcium transport rate via the protein in the presence of the chemical; and
d. comparing the measurement of step (c) with the transmembrane calcium transport rate via the protein in the absence of the chemical.

### Claim 32 (depends on 31)

The method of claim 31, wherein the chemical is an antibody.

### Claim 33 (depends on 31)

The method of claim 31, wherein the chemical is a nucleic acid.

### Claim 34 (depends on 31)

The method of claim 31, wherein the chemical is an inhibitor.

### Claim 35 (depends on 31)

The method of claim 31, wherein the cell is an epithelial cell.

### Claim 36 (depends on 31)

The method of claim 31, wherein the cell is a Xenopus laevis oocyte, placenta cell, pancreas cell, prostate cell, kidney cell, gastrointestinal tract cell, liver cell, hair follicle cell, testis cell, or cancer cell.

### Claim 37 (depends on 36)

The method of claim 36, wherein the cell is an esophageal cell, stomach cell, duodenum cell, jejunum cell, or colon cell.

### Claim 38 (depends on 36)

The method of claim 36, wherein the cell is the chronic myelogenous leukemia cell line K562, the colorectal adenocarcinoma cell line SW480, a bone cell, a leukemia cell, a prostate cancer cell, a breast cancer cell, an esophagus cancer cell, a stomach cancer cell, and a colon cancer cell.

### Claim 39 (depends on 31)

The method of claim 31, wherein the chemical alters the transport properties of the protein.

### Claim 40 (depends on 31)

The method of claim 31, wherein the chemical binds to the protein.

### Claim 41 (depends on 31)

The method of claim 31, wherein the protein is integral with the cellular membrane.

### Claim 42 (depends on 31)

The method of claim 31, wherein the protein is present as a free species.
